|
|
Other links at Articles > Business of Medicine |
| 1. |
More Action Possible Erythropoiesis-Stimulating Agents: US FDA
|
|
|
U.S. regulators said on Thursday they were reviewing two recent studies that provided more evidence of serious risks for some cancer patients treated with erythropoiesis-stimulating agents, also known as ESAs or Epo drugs, for anemia. Reuters Health Information
|
|
|